Circulation of the representatives of acute respiratory viral infections and influenza viruses in Kazakhstan
DOI:
https://doi.org/10.26577/eb-2018-2-1334Abstract
Acute respiratory viral infections (ARVI) and influenza remain one of the most urgent medical and social-economic problems throughout the world, including Kazakhstan. In this article the data of the long-term dynamics of the incidence of influenza and ARVI rates in the Kazakhstan for 2000-2001 to 2016-2017, data of epidemiological monitoring of the circulation of influenza viruses in the influenza season 2016-2017 are analyzed. The described 2016-20 influenza season was characterized by a relatively earlier onset – the maximum incidence of ARI was observed at 50 on 2016 y. (118.9 per 100 thousand population) and at 02 weeks on 2017 y. (192.7 per 100 thousand population). PCR diagnostics established the circulation of influenza A viruses H3N2 and B and the onset of the epidemic season (44 ISSN 1563-0218 Experimental Biology. №2 (75). 2018 157 Табаева А., Картпаева Б. weeks) was associated with a greater activity of the influenza B virus, and its completion was dominated by influenza A H3N2 virus (week 18). A distinctive feature of the season was the absence of the influenza A virus H1N1 pdm09. Genetic analysis of isolated strains of influenza showed their similarity with vaccine strains A/Hong Kong/4801/2014 and B/Brisbane/60/2008. Sequencing of the studied strains of the influenza virus demonstrated the preservation of their sensitivity to antiviral drugs.
Key words: influenza viruses, PCR, genetic analysis, sequencing, sensitivity to antiviral drugs, seasonal incidence of influenza, seasonal incidence of ARVI.
References
Potter C.W. A history of influenza // J. Appl. Microbiol. – 2001. – № 91. – С. 572–579.
WHO. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. // News release 14 december 2017. – Geneva: World Health Organization, 2017a.- (http://www.who.int/ mediacentre/ news/ releases/2017/seasonal-flu/ru).
WHO. Regional Office for Europe guidance for sentinel influenza surveillance in humans. – Geneva: World Health Organization,2011b.
WHO. Global Epidemiological Surveillance Standards for Influenza. – Geneva: World Health Organization, 2014. – (http://www.who.int/influenza/resources/documents).
Sano K., Ainai A., Suzuki T., Hasegawa H. The road to a more effective influenza vaccine: Up to date studies and future prospects // Vaccine. – 2017. – № 35. – С. 5388–5395.
Tria F., Pompei S., Loreto V. Dynamically correlated mutations drive human Influenza A evolution // Sci Rep. – 2013. – № 3. – С. 2705.
Hegermann-Lindencrone M., Gross D., Meerhoff T., Pereyaslov D., et al. Деятельность сети эпиднадзора за гриппом в европейском регионе: согласование с глобальными стандартами // Панорама общественного здравоохранения. – 2015. – Т. 1, № 1. – С. 89-100.
Официальная статистическая информация /Население// Архив 2017 г. – (http://stat.gov.kz).
Бекшин Ж. Выступление главного государственного санитарного врача Республики Казахстан // Международная научно-практическая конференция «Профилактика гриппа и острых респираторных инфекций» – 28-29 августа 2017 года, Алматы, Казахстан. – (http://365info.kz/2017/08).
О дальнейшем совершенствовании дозорного эпидемиологического надзора за гриппом в республике (с изменениями и дополнениями от 10.07.2013 г.). – Приказ Министра здравоохранения Республики Казахстан от 23 декабря 2011 года № 910.
Национальный план реагирования на пандемию гриппа в Республике Казахстан. – Распоряжение ПремьерМинистра Республики Казахстан от 19 августа 2009 года № 120-р2009.
Куатбаева А.М., Есмагамбетова А.С. Об опыте применения электронной системы слежения за ОРВИ/ГПЗ/ ТОРИ в рамках ДЭН за гриппом в Республике Казахстан // Материалы научно-методической конференции «Грипп, острые респираторные вирусные инфекции и их осложнения: диагностика, лечение и профилактика», посвященной профессору Г.У. Алшинбаевой. – Астана, 3-4 октября 2013. – С. 39.
Babcock H.M., Merz L.R., Fraser V.J. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients // Infect Control Hosp. Epidemiol. – 2006. – Т. 27, № 3. – С. 266–270.
Алгоритм организации системы дозорного эпиднадзора за ГПЗ и ТОРИ // Санитарно-эпидемиологические требования к организации и проведению санитарно-противоэпидемических (профилактических) мероприятий по предупреждению инфекционных заболеваний. – Приказ Министра национальной экономики Республики Казахстан № 194 от 12.03.2015 г.
Steininger C., Kundi M., Aberle S.W., et al. Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups // J. Clin. Microbiol. – 2002. – Т. 40, № 6. – С.2051–2056.
Freshney R.I. Culture of animal cells: a manual of basic technique // 5th ed. Hoboken N.J., Wiley-Liss. – 2005.
Knipe D., Howley P. Fields virology. – Т. 2, 5th edition. – Wolters Kluwer, 2007. – C. 2947–2976.
Cooper N.J, Sutton A.J, Abrams K.R, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials // BMJ. – 2003. – Т. 326, № 7401. – С. 1235.
Kallewaard N.L., Corti D., Collins P.J., Neu U., McAuliffe J.M., Benjamin E., et al. Structure and function analysis of an antibody recognizing all influenza a subtypes // Cell. – 2016. – № 166. – С. 596–608.
Yasugi M., Kubota-Koketsu R., Yamashita A., Kawashita N., Du A., Sasaki T., et al. Human monoclonal antibodies broadly neutralizing against influenza B virus. – PLoS Pathog. – 2013. – 9:e1003150.
Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Basler C.F., Crowe Jr. J.E. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin // J. Virol. –2011. – № 85. – С. 10905–10908.
WHO. Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. –Geneva: World Health Organization, 2011a. – (http://apps.who.int/iris/bitstream/handle).
Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus // Science. – 2004. – № 305. – С.371–376.
Kumar S., Stecher G., Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets // Mol.Biol. Evol. – 2016. – Т. 33, № 7. – С.1870–1874.
WHO. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season.– Geneva: World Health Organization, 2 March 2017b. – (http://www.who.int/ influenza/vaccines/virus/recommendations).
Nachbagauer R., Krammer F. Universal influenza virus vaccine sandtherapeutic antibodies // Clin. Microbiol. Infect. – 2017. –№ 23. – С. 222–228.
References
Algoritm organizatsii sistemy dozornogo epidnadzora za GPZ i TORI [Algorithm for the organization of the sentinel surveillance system for ILI and SARI] (2015). Sanitarno-epidemiologicheskiye trebovaniya k organizatsii i provedeniyu sanitarno-protivoepidemicheskikh (profilakticheskikh) meropriyatiy po preduprezhdeniyu infektsionnykh zabolevaniy, Prikaz Ministra natsional’noy ekonomiki Respubliki Kazakhstan, no 194 ot 12.03.15.
Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006; 27:3:266–270.
Bekshin Zh. (2017) Vystupleniye glavnogo gosudarstvennogo sanitarnogo vracha Respubliki Kazakhstan [Speech of the Chief State Sanitary Doctor of the Republic of Kazakhstan]. Mezhdunarodnaya nauchno-prakticheskaya konferentsia «Profilaktika grippa i ostrykh respiratornykh infektsiy», 28-29 avgusta 2017 goda, Almaty, Kazakhstan, http://365info.kz/2017/08.
Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:7401–1235.
Freshney RI. Culture of animal cells: a manual of basic technique. 5th ed.. Hoboken NJ, Wiley-Liss; 2005.
Hegermann-Lindencrone M., Gross D., Meerhoff T., Pereyaslov D. et al. (2015) Deyatel’nost’ seti epidnadzora za grippom v yevropeyskom regione: soglasovaniye s global’nymi standartami [Activity of the influenza surveillance network in the European region: harmonization with global standards]. Panorama obshchestvennogo zdravookhraneniya, vol. 1, no 1, pp. 89-100.
Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, et al. Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell 2016; 166:596–608.
Knipe D, Howley P. Fields virology. vol. 2. 5th edition. Wolters Kluwer; 2007.
Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe Jr. JE. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011; 85:10905–8.
Kuatbayeva A.M., Yesmagambetova A.S. (2013) Ob opyte primeneniya elektronnoy sistemy slezheniya za ORVI/GPZ/ TORI v ramkakh DEN za grippom v Respublike Kazakhstan. [Experience of using the electronic surveillance system for ARVI / GEA / SARI in the framework of SS for influenza in the Republic of Kazakhstan]. Materialy nauchno-metodicheskoy konferentsii «Gripp, ostryye respiratornyye virusnyye infektsii i ikh oslozhneniya: diagnostika, lecheniye i profilaktika», posvyashchennoy professor G.U. Alshinbayevoy, Astana, 3-4 oktyabrya, p. 39.
Kumar. S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 2016; 33(7):1870–1874.
Nachbagauer R, Krammer F. Universal influenza virus vaccine sandtherapeutic antibodies. Clin Microbiol Infect 2017; 23:222–228.
Natsional’nyy plan reagirovaniya na pandemiyu grippa v Respublike Kazakhstan [The [National Plan for Response to the Influenza Pandemic in the Republic of Kazakhstan] (2009), utverzhden rasporyazheniyem Prem’yer-Ministra Respubliki Kazakhstan ot 19 avgusta no 120-r2009. O dal’neyshem sovershenstvovanii dozornogo epidemiologicheskogo nadzora za grippom v respublike [On further improvement of sentinel epidemiological surveillance of influenza in the republic] (2011) Prikaz Ministra zdravookhraneniya Respubliki Kazakhstan, no 910 ot 23 dekabrya (s izmeneniyami i dopolneniyami ot 10.07.2013 g.).
Ofitsial’naya statisticheskaya informatsiya [Official statistical information] (2017) Naseleniye, Arkhiv, http://stat.gov.kz.
Potter CW. A history of influenza. J Appl Microbiol 2001; 91:572–9.
Sano K, Ainai A, Suzuki T, Hasegawa H. The road to a more effective influenza vaccine: Up to date studies and future prospects. Vaccine 2017; 35 5388–5395.
Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus.Science 2004; 305:371–6.
Steininger C, Kundi M, Aberle SW, et al. Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol 2002; 40(6):2051–6.
Tria F, Pompei S, Loreto V: Dynamically correlated mutations drive human Influenza A evolution. Sci Rep 2013; 3:2705.
WHO. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. News release 14 december 2017. Geneva, World Health Organization, 2017a, http://www.who.int/ mediacentre/ news/ releases/2017/seasonal-flu/ru.
WHO. Global Epidemiological Surveillance Standards for Influenza. Geneva: World Health Organization; 2014, http://www.who.int/influenza/resources/documents.
WHO. Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization, 2011a, http://apps.who.int/iris/bitstream/handle.
WHO. Regional Office for Europe guidance for sentinel influenza surveillance in humans. World Health Organization, 2011b.
WHO. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. 2 March. World Health Organization, 2017b, http://www.who.int/ influenza/vaccines/virus/recommendations.
Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, et al. Human monoclonal antibodies broadly neutralizing against influenza B virus.PLoS Pathog; 2013- 9:e1003150.
WHO. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. // News release 14 december 2017. – Geneva: World Health Organization, 2017a.- (http://www.who.int/ mediacentre/ news/ releases/2017/seasonal-flu/ru).
WHO. Regional Office for Europe guidance for sentinel influenza surveillance in humans. – Geneva: World Health Organization,2011b.
WHO. Global Epidemiological Surveillance Standards for Influenza. – Geneva: World Health Organization, 2014. – (http://www.who.int/influenza/resources/documents).
Sano K., Ainai A., Suzuki T., Hasegawa H. The road to a more effective influenza vaccine: Up to date studies and future prospects // Vaccine. – 2017. – № 35. – С. 5388–5395.
Tria F., Pompei S., Loreto V. Dynamically correlated mutations drive human Influenza A evolution // Sci Rep. – 2013. – № 3. – С. 2705.
Hegermann-Lindencrone M., Gross D., Meerhoff T., Pereyaslov D., et al. Деятельность сети эпиднадзора за гриппом в европейском регионе: согласование с глобальными стандартами // Панорама общественного здравоохранения. – 2015. – Т. 1, № 1. – С. 89-100.
Официальная статистическая информация /Население// Архив 2017 г. – (http://stat.gov.kz).
Бекшин Ж. Выступление главного государственного санитарного врача Республики Казахстан // Международная научно-практическая конференция «Профилактика гриппа и острых респираторных инфекций» – 28-29 августа 2017 года, Алматы, Казахстан. – (http://365info.kz/2017/08).
О дальнейшем совершенствовании дозорного эпидемиологического надзора за гриппом в республике (с изменениями и дополнениями от 10.07.2013 г.). – Приказ Министра здравоохранения Республики Казахстан от 23 декабря 2011 года № 910.
Национальный план реагирования на пандемию гриппа в Республике Казахстан. – Распоряжение ПремьерМинистра Республики Казахстан от 19 августа 2009 года № 120-р2009.
Куатбаева А.М., Есмагамбетова А.С. Об опыте применения электронной системы слежения за ОРВИ/ГПЗ/ ТОРИ в рамках ДЭН за гриппом в Республике Казахстан // Материалы научно-методической конференции «Грипп, острые респираторные вирусные инфекции и их осложнения: диагностика, лечение и профилактика», посвященной профессору Г.У. Алшинбаевой. – Астана, 3-4 октября 2013. – С. 39.
Babcock H.M., Merz L.R., Fraser V.J. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients // Infect Control Hosp. Epidemiol. – 2006. – Т. 27, № 3. – С. 266–270.
Алгоритм организации системы дозорного эпиднадзора за ГПЗ и ТОРИ // Санитарно-эпидемиологические требования к организации и проведению санитарно-противоэпидемических (профилактических) мероприятий по предупреждению инфекционных заболеваний. – Приказ Министра национальной экономики Республики Казахстан № 194 от 12.03.2015 г.
Steininger C., Kundi M., Aberle S.W., et al. Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups // J. Clin. Microbiol. – 2002. – Т. 40, № 6. – С.2051–2056.
Freshney R.I. Culture of animal cells: a manual of basic technique // 5th ed. Hoboken N.J., Wiley-Liss. – 2005.
Knipe D., Howley P. Fields virology. – Т. 2, 5th edition. – Wolters Kluwer, 2007. – C. 2947–2976.
Cooper N.J, Sutton A.J, Abrams K.R, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials // BMJ. – 2003. – Т. 326, № 7401. – С. 1235.
Kallewaard N.L., Corti D., Collins P.J., Neu U., McAuliffe J.M., Benjamin E., et al. Structure and function analysis of an antibody recognizing all influenza a subtypes // Cell. – 2016. – № 166. – С. 596–608.
Yasugi M., Kubota-Koketsu R., Yamashita A., Kawashita N., Du A., Sasaki T., et al. Human monoclonal antibodies broadly neutralizing against influenza B virus. – PLoS Pathog. – 2013. – 9:e1003150.
Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Basler C.F., Crowe Jr. J.E. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin // J. Virol. –2011. – № 85. – С. 10905–10908.
WHO. Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. –Geneva: World Health Organization, 2011a. – (http://apps.who.int/iris/bitstream/handle).
Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus // Science. – 2004. – № 305. – С.371–376.
Kumar S., Stecher G., Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets // Mol.Biol. Evol. – 2016. – Т. 33, № 7. – С.1870–1874.
WHO. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season.– Geneva: World Health Organization, 2 March 2017b. – (http://www.who.int/ influenza/vaccines/virus/recommendations).
Nachbagauer R., Krammer F. Universal influenza virus vaccine sandtherapeutic antibodies // Clin. Microbiol. Infect. – 2017. –№ 23. – С. 222–228.
References
Algoritm organizatsii sistemy dozornogo epidnadzora za GPZ i TORI [Algorithm for the organization of the sentinel surveillance system for ILI and SARI] (2015). Sanitarno-epidemiologicheskiye trebovaniya k organizatsii i provedeniyu sanitarno-protivoepidemicheskikh (profilakticheskikh) meropriyatiy po preduprezhdeniyu infektsionnykh zabolevaniy, Prikaz Ministra natsional’noy ekonomiki Respubliki Kazakhstan, no 194 ot 12.03.15.
Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006; 27:3:266–270.
Bekshin Zh. (2017) Vystupleniye glavnogo gosudarstvennogo sanitarnogo vracha Respubliki Kazakhstan [Speech of the Chief State Sanitary Doctor of the Republic of Kazakhstan]. Mezhdunarodnaya nauchno-prakticheskaya konferentsia «Profilaktika grippa i ostrykh respiratornykh infektsiy», 28-29 avgusta 2017 goda, Almaty, Kazakhstan, http://365info.kz/2017/08.
Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:7401–1235.
Freshney RI. Culture of animal cells: a manual of basic technique. 5th ed.. Hoboken NJ, Wiley-Liss; 2005.
Hegermann-Lindencrone M., Gross D., Meerhoff T., Pereyaslov D. et al. (2015) Deyatel’nost’ seti epidnadzora za grippom v yevropeyskom regione: soglasovaniye s global’nymi standartami [Activity of the influenza surveillance network in the European region: harmonization with global standards]. Panorama obshchestvennogo zdravookhraneniya, vol. 1, no 1, pp. 89-100.
Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, et al. Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell 2016; 166:596–608.
Knipe D, Howley P. Fields virology. vol. 2. 5th edition. Wolters Kluwer; 2007.
Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe Jr. JE. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011; 85:10905–8.
Kuatbayeva A.M., Yesmagambetova A.S. (2013) Ob opyte primeneniya elektronnoy sistemy slezheniya za ORVI/GPZ/ TORI v ramkakh DEN za grippom v Respublike Kazakhstan. [Experience of using the electronic surveillance system for ARVI / GEA / SARI in the framework of SS for influenza in the Republic of Kazakhstan]. Materialy nauchno-metodicheskoy konferentsii «Gripp, ostryye respiratornyye virusnyye infektsii i ikh oslozhneniya: diagnostika, lecheniye i profilaktika», posvyashchennoy professor G.U. Alshinbayevoy, Astana, 3-4 oktyabrya, p. 39.
Kumar. S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 2016; 33(7):1870–1874.
Nachbagauer R, Krammer F. Universal influenza virus vaccine sandtherapeutic antibodies. Clin Microbiol Infect 2017; 23:222–228.
Natsional’nyy plan reagirovaniya na pandemiyu grippa v Respublike Kazakhstan [The [National Plan for Response to the Influenza Pandemic in the Republic of Kazakhstan] (2009), utverzhden rasporyazheniyem Prem’yer-Ministra Respubliki Kazakhstan ot 19 avgusta no 120-r2009. O dal’neyshem sovershenstvovanii dozornogo epidemiologicheskogo nadzora za grippom v respublike [On further improvement of sentinel epidemiological surveillance of influenza in the republic] (2011) Prikaz Ministra zdravookhraneniya Respubliki Kazakhstan, no 910 ot 23 dekabrya (s izmeneniyami i dopolneniyami ot 10.07.2013 g.).
Ofitsial’naya statisticheskaya informatsiya [Official statistical information] (2017) Naseleniye, Arkhiv, http://stat.gov.kz.
Potter CW. A history of influenza. J Appl Microbiol 2001; 91:572–9.
Sano K, Ainai A, Suzuki T, Hasegawa H. The road to a more effective influenza vaccine: Up to date studies and future prospects. Vaccine 2017; 35 5388–5395.
Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus.Science 2004; 305:371–6.
Steininger C, Kundi M, Aberle SW, et al. Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol 2002; 40(6):2051–6.
Tria F, Pompei S, Loreto V: Dynamically correlated mutations drive human Influenza A evolution. Sci Rep 2013; 3:2705.
WHO. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. News release 14 december 2017. Geneva, World Health Organization, 2017a, http://www.who.int/ mediacentre/ news/ releases/2017/seasonal-flu/ru.
WHO. Global Epidemiological Surveillance Standards for Influenza. Geneva: World Health Organization; 2014, http://www.who.int/influenza/resources/documents.
WHO. Global Influenza Surveillance Network: Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization, 2011a, http://apps.who.int/iris/bitstream/handle.
WHO. Regional Office for Europe guidance for sentinel influenza surveillance in humans. World Health Organization, 2011b.
WHO. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. 2 March. World Health Organization, 2017b, http://www.who.int/ influenza/vaccines/virus/recommendations.
Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, et al. Human monoclonal antibodies broadly neutralizing against influenza B virus.PLoS Pathog; 2013- 9:e1003150.
Downloads
How to Cite
Tabayeva, A., & Kartpayeva, B. (2018). Circulation of the representatives of acute respiratory viral infections and influenza viruses in Kazakhstan. Experimental Biology, 75(2), 156–165. https://doi.org/10.26577/eb-2018-2-1334
Issue
Section
MICROBIOLOGY
